These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Maintaining the balance of TDP-43, mitochondria, and autophagy: a promising therapeutic strategy for neurodegenerative diseases. Huang C; Yan S; Zhang Z Transl Neurodegener; 2020 Oct; 9(1):40. PubMed ID: 33126923 [TBL] [Abstract][Full Text] [Related]
7. The role of TDP-43 propagation in neurodegenerative diseases: integrating insights from clinical and experimental studies. Jo M; Lee S; Jeon YM; Kim S; Kwon Y; Kim HJ Exp Mol Med; 2020 Oct; 52(10):1652-1662. PubMed ID: 33051572 [TBL] [Abstract][Full Text] [Related]
8. Review: transactive response DNA-binding protein 43 (TDP-43): mechanisms of neurodegeneration. Gendron TF; Josephs KA; Petrucelli L Neuropathol Appl Neurobiol; 2010 Apr; 36(2):97-112. PubMed ID: 20202122 [TBL] [Abstract][Full Text] [Related]
9. Targeting TDP-43 in neurodegenerative diseases. Budini M; Baralle FE; Buratti E Expert Opin Ther Targets; 2014 Jun; 18(6):617-32. PubMed ID: 24649927 [TBL] [Abstract][Full Text] [Related]
11. Molecular basis of ALS and FTD: implications for translational studies. Liščić RM Arh Hig Rada Toksikol; 2015 Dec; 66(4):285-90. PubMed ID: 26751860 [TBL] [Abstract][Full Text] [Related]
12. Investigating the role of filamin C in Belgian patients with frontotemporal dementia linked to GRN deficiency in FTLD-TDP brains. Janssens J; Philtjens S; Kleinberger G; Van Mossevelde S; van der Zee J; Cacace R; Engelborghs S; Sieben A; Banzhaf-Strathmann J; Dillen L; Merlin C; Cuijt I; Robberecht C; Schmid B; Santens P; Ivanoiu A; Vandenbulcke M; Vandenberghe R; Cras P; De Deyn PP; Martin JJ; Maudsley S; Haass C; Cruts M; Van Broeckhoven C; Acta Neuropathol Commun; 2015 Nov; 3():68. PubMed ID: 26555887 [TBL] [Abstract][Full Text] [Related]
13. Clinical and neuropathological features of ALS/FTD with TIA1 mutations. Hirsch-Reinshagen V; Pottier C; Nicholson AM; Baker M; Hsiung GR; Krieger C; Sengdy P; Boylan KB; Dickson DW; Mesulam M; Weintraub S; Bigio E; Zinman L; Keith J; Rogaeva E; Zivkovic SA; Lacomis D; Taylor JP; Rademakers R; Mackenzie IRA Acta Neuropathol Commun; 2017 Dec; 5(1):96. PubMed ID: 29216908 [TBL] [Abstract][Full Text] [Related]
14. TDP-43: an emerging new player in neurodegenerative diseases. Wang IF; Wu LS; Shen CK Trends Mol Med; 2008 Nov; 14(11):479-85. PubMed ID: 18929508 [TBL] [Abstract][Full Text] [Related]
15. ALS/FTLD-linked TDP-43 regulates neurite morphology and cell survival in differentiated neurons. Han JH; Yu TH; Ryu HH; Jun MH; Ban BK; Jang DJ; Lee JA Exp Cell Res; 2013 Aug; 319(13):1998-2005. PubMed ID: 23742895 [TBL] [Abstract][Full Text] [Related]
16. FTLD/ALS-linked TDP-43 mutations do not alter TDP-43's ability to self-regulate its expression in Drosophila. Miguel L; Avequin T; Pons M; Frebourg T; Campion D; Lecourtois M Brain Res; 2018 Sep; 1695():1-9. PubMed ID: 29778779 [TBL] [Abstract][Full Text] [Related]
17. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Mackenzie IR; Rademakers R; Neumann M Lancet Neurol; 2010 Oct; 9(10):995-1007. PubMed ID: 20864052 [TBL] [Abstract][Full Text] [Related]
18. Inter-Species Differences in Regulation of the Progranulin-Sortilin Axis in TDP-43 Cell Models of Neurodegeneration. Gumina V; Onesto E; Colombrita C; Maraschi A; Silani V; Ratti A Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31766750 [TBL] [Abstract][Full Text] [Related]
19. Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS. Ke YD; van Hummel A; Stevens CH; Gladbach A; Ippati S; Bi M; Lee WS; Krüger S; van der Hoven J; Volkerling A; Bongers A; Halliday G; Haass NK; Kiernan M; Delerue F; Ittner LM Acta Neuropathol; 2015 Nov; 130(5):661-78. PubMed ID: 26437864 [TBL] [Abstract][Full Text] [Related]